Fibrosis markers and CRIM1 increase in chronic heart failure of increasing severity. (May 2014)

• Record Type: Journal Article
• Authors: Eleuteri, Ermanno; Di Stefano, Antonino; Vallese, Davide; Gnemmi, Isabella; Pitruzzella, Alessandro; Tarro Genta, Franco; Delle Donne, Lorena; Cappello, Francesco; Ricciardolo, Fabio L. M.; Giannuzzi, Pantaleo
• Is Part Of: Biomarkers. Volume 19:Number 3(2014)
• Page Start: 214
• Page End: 221
• Publication Date: 2014-05
• Subjects: Biochemical markers -- Periodicals; 610.28
• DOI: 10.3109/1354750X.2014.896946
• Languages: English
• ISSNs: 1354-750X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: Fibrosis suppressors/activators in chronic heart failure (CHF) is a topic of investigation.</p> <p> <italic>Aim</italic>: To quantify serum levels of fibrosis regulators in CHF.</p> <p> <italic>Methods</italic>: ELISA tests were used to quantify fibrosis regulators, procollagen type-(PIP)I, (PIP)III, collagen-I, III, BMP1, 2, 3, 7, SDF1α, CXCR4, fibulin 1, 2, 3, BMPER, CRIM1 and BAMBI in 66 CHF (NYHA class I, <italic>n</italic> = 9; II, <italic>n</italic> = 34; III <italic>n</italic> = 23), and in 14 controls.</p> <p> <italic>Results</italic>: In CHF, TGFβR2, PIPIII, SDF1α and CRIM1 were increased. PIPIII correlated with CRIM1.</p> <p> <italic>Conclusions</italic>: The BMPs inhibitor CRIM1 is increased and correlates with higher levels of serum PIPIII showing an imbalance in favor of pro-fibrotic mechanisms in CHF.</p> </abstract>